Table 4 Adherence to heart failure treatment guidelines (ESC Guidelines), GPs=general practitioners
Case number | Treatment guidelines issue | Clinical pharmacist recommendations | GPs acceptance (YES/NO) |
|---|---|---|---|
1. | Methyldigoxin treatment | Methyldigoxin discontinuation and perindopril initiation | YES |
2. | Methyldigoxin treatment | Methyldigoxin discontinuation and enalapril initiation | NO |
3. | Methyldigoxin treatment + β-blocker +ACE inhibitor | Methyldigoxin treatment discontinuation | YES |
4. | Methyldigoxin treatment +ACE inhibitor | Methyldigoxin treatment discontinuation + β-blocker initiation | YES |
5. | Methyldigoxin treatment | β-blocker initiation and ACE inhibitor initiation | NO |
6, 7, 8, 9, 10. | Methyldigoxin treatment + β-blocker | Methyldigoxin treatment discontinuation | YES, NO, YES, NO, YES |
11. | Methyldigoxin treatment +ACE inhibitor | Methyldigoxin treatment discontinuation + β-blocker initiation | NO |
12. | 1.25 mg bisoprolol daily | Drug adjustment (2,5 mg daily) | YES |
13, 14, 15. | ACE inhibitor treatment | β-blocker adding | NO, NO, NO |
16, 17, 18. | ACE inhibitor treatment with verapamil | Verapamil discontinuation and selective β-blocker initiation | NO, NO, NO |
19. | Inappropriate dosing of ACE inhibitor and β-blocker | Reduce the ACE inhibitor dose and increase the dose of the β-blocker | NO |
20. | Nonselective β-blocker | Switching to bisoprolol | NO, YES |
21. | Amlodipine treatment | Amlodipine discontinuation and β-blocker (bisoprolol) initiation | YES |